Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|July 12, 2016
The Future of Connected Devices in Medication Therapy Management
Author(s)Lauren Santye, Assistant Editor
Josh Stein, CEO and co-founder of AdhereTech, discusses how technology can enhance the ability of specialty pharmacies to manage their patients' therapy regimen.
Advertisement
Josh Stein, CEO and co-founder of AdhereTech, discusses how technology can enhance the ability of specialty pharmacies to manage their patients' therapy regimen.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5